About this source
- Kind
- Research
- Design
- Human observational
- Population
- 115 patients with erythropoietic protoporphyria who received 1,023 implants over up to 8 years
- Sample size
- 115
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Observational, no control group. Quality-of-life scores are self-reported. About 23% stopped treatment.
Cited in
Long-term observational study
Afamelanotide · Research finding
LimitedLong-term adverse events
Afamelanotide · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.